NEW DATE/TIME

Join us on Tuesday, October 8^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Recognize known mechanisms of resistance to endocrine therapy in hormone receptor (HR)-positive metastatic breast cancer (mBC), and use this information to develop optimal approaches to biomarker assessment and clinical management.
• Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant HR-positive mBC, and determine optimal approaches to identify patients harboring these abnormalities.
• Understand the biological rationale for the activity of oral selective estrogen receptor degraders (SERDs) in HR-positive mBC with ESR1 mutations, and assess the current clinical trial database with various oral SERDs for patients whose disease has progressed on endocrine therapy and a CDK4/6 inhibitor.
• Evaluate the pharmacologic similarities and differences between available and investigational oral SERDs.
• Review available research data and ongoing clinical trials evaluating the role of serial ESR1 testing using circulating tumor DNA to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy.
• Assess ongoing clinical research studies evaluating novel applications of oral SERDs for HR-positive mBC, and counsel patients regarding the potential benefits of trial participation.

CE Credit
CME, ABIM MOC and ABS credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY

Prof Bidard — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, GE Healthcare, Gilead Sciences Inc, Inatherys, Lilly, Menarini Group, Novartis, Pfizer Inc, Roche Laboratories Inc, SAGA Diagnostics, Stemline Therapeutics Inc; Contracted Research: GE Healthcare, Menarini Silicon Biosystems, Merck KGaA, MSD, Novartis, Personalis, Pfizer Inc, ProLynx Inc, Roche Laboratories Inc, SAGA Diagnostics, Tempus; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Menarini Group, Pfizer Inc, Stemline Therapeutics Inc; Travel Support: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Novartis, Pfizer Inc. Dr Kalinsky — Advisory Committees: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Cullinan Therapeutics, Cyclacel Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Eisai Inc, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Prelude Therapeutics, RayzeBio, Regor Therapeutics Group, Seagen Inc; Data and Safety Monitoring Board/Committee: Merck; Stock Options/Stock — Public Companies: Grail Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc (spouse prior employment).

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSeraTherapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.